Hidden Gene Ties Deadly Cancer To Families

DNA double helix with glowing particles
Photo: Billion Photos / Shutterstock

Five men, five different families, one broken gene, and a cancer that struck decades before it should have.

Quick Take

  • Researchers screened 4,535 men with aggressive prostate cancer and found five unrelated carriers of an inherited CDK12 mutation
  • All five developed metastatic prostate cancer between ages 44 and 62, far younger than typical
  • Tumor tests showed the men’s remaining healthy copy of CDK12 had failed too, a pattern scientists call loss of the second allele
  • The inherited flaw shows up in roughly one of every 1,000 aggressive prostate cancer patients tested
  • Scientists want CDK12 added to standard hereditary cancer gene panels for qualifying patients

A Gene Nobody Expected To Find Running In Families

Researchers at the University of Washington set out to understand why some prostate cancers turn deadly so fast. They sequenced the CDK12 gene in tumor samples from thousands of men already fighting aggressive disease. Then they compared those tumor results against DNA pulled from each man’s normal white blood cells, looking for mutations present everywhere, not just inside the tumor.

That comparison turned up something striking. Five men, unrelated to each other, carried one healthy copy of CDK12 and one broken copy in every cell of their body, not just their cancer. That pattern is the signature of an inherited mutation, passed down at conception, not picked up later by chance.

Young Men, Aggressive Disease, A Common Thread

Every one of the five carriers developed metastatic prostate cancer, meaning the disease had already spread, between ages 44 and 62. That is notably young for prostate cancer, which typically strikes men well into their sixties and seventies. The shared timing across five unrelated men pointed researchers toward a biological cause rather than coincidence.

Tumor sequencing backed up the suspicion. In each carrier, the cancer cells showed damage to the second, previously healthy copy of CDK12, a process called loss of the second allele. Losing both working copies of the gene inside the tumor matched a molecular fingerprint tied to inherited CDK12 problems, giving researchers a direct biological link between the inherited flaw and the cancer itself.

Rare But Real: What The Numbers Actually Show

Among the 4,535 men studied, inherited CDK12 mutations showed up in roughly one out of every 1,000 cases. That is a small slice of the group, but the men studied already had aggressive prostate cancer, so this number does not tell us how common the mutation is in the general public. It tells us how often it shows up among men already fighting the toughest form of the disease.

Based on these findings, the research team recommended that CDK12 be added to hereditary cancer-risk gene panels for patients who already meet testing guidelines because of their personal or family cancer history. Doctors already order these panels looking for known culprits like BRCA1, BRCA2, and HOXB13. The researchers argue CDK12 deserves a seat at that same table.

Why This Fits A Familiar Pattern In Cancer Genetics

National cancer guidelines already list a handful of genes tied to inherited prostate cancer risk, including ATM, BRCA1, BRCA2, CHEK2, and HOXB13. Each of those genes earned its place on testing panels only after researchers found it repeatedly, then proved it mattered for patient outcomes. CDK12 now stands at that same starting line, backed by a clear biological signal but still needing the follow-up work that turns a discovery into a clinical standard.

The University of Washington team was direct about that gap, stating more research is needed before doctors can issue specific screening recommendations for carriers. That is a reasonable, honest limit to place on a finding built from five men. It does not undercut the discovery. It simply marks the next job: figuring out how early, how often, and how aggressively doctors should watch men who carry this mutation, so families can act on real answers instead of guesswork.

Sources:

sciencedaily.com, pmc.ncbi.nlm.nih.gov, dailybeirut.com